Clinical Research Directory
Browse clinical research sites, groups, and studies.
Microdosing LSD in Women With Premenstrual Disorders
Sponsor: Friederike Holze
Summary
The investigators aim to investigate the role of the serotonin 2A receptor in women with premenstrual disorders. This study uses a double-blind, randomized, controlled design with 3 arms: Intervention 1: 10 micg LSD for \~10 days during the late luteal phase (for 3 cycles) Intervention 2: 10 micg LSD every other day for \~10 days during the late luteal phase (for 3 cycles) Control intervention: Placebo for \~10 days during the late luteal phase (for 3 cycles) Each participant will be treated in only one arm. The study employs a parallel design with three treatment arms and consists of a two-cycle observational phase followed by a three-cycle treatment phase.
Official title: Role of the Serotonin 2A Receptor in Women With Premenstrual Disorders: a Randomized, Double-blind, Placebo-controlled Study (L4Her-Study)
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-10-01
Completion Date
2030-01-01
Last Updated
2025-09-23
Healthy Volunteers
No
Interventions
LSD 10 μg every Day
Participants will receive 10 μg LSD every day during the luteal phase
LSD 10 μg every other day
Participants receive 10μg LSD every second day during the luteal phase
Placebo
Participants receive inactive placebo during the luteal phase
Locations (1)
Clinical Pharmacology & Toxicology, University Hospital Basel
Basel, Canton of Basel-City, Switzerland